Abstract
Aims: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases. Methods: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients. Stakeholders: Include patients, health care professionals (pharmacists and physicians), authorities, patient's associations, private and public sectors. Results: MASK is deployed in 23 countries and 17 languages. 26,000 users have registered. EU grants (2018): MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour). Lessons learnt: (i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases.
Original language | English |
---|---|
Article number | 16 |
Number of pages | 19 |
Journal | Clinical and Translational Allergy |
Volume | 9 |
Issue number | 1 |
DOIs | |
Publication status | Published - 11 Mar 2019 |
Keywords
- App
- Asthma
- Care pathways
- DG Santé
- MASK
- mHealth
- Rhinitis
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Clinical and Translational Allergy, Vol. 9, No. 1, 16, 11.03.2019.
Research output: Contribution to journal › Review Article › Other › peer-review
TY - JOUR
T1 - Guidance to 2018 good practice
T2 - ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma
AU - Bousquet, J.
AU - Bedbrook, A.
AU - Czarlewski, W.
AU - Onorato, G. L.
AU - Arnavielhe, S.
AU - Laune, D.
AU - Mathieu-Dupas, E.
AU - Fonseca, J.
AU - Costa, E.
AU - Lourenço, O.
AU - Morais-Almeida, M.
AU - Todo-Bom, A.
AU - Illario, M.
AU - Menditto, E.
AU - Canonica, G. W.
AU - Cecchi, L.
AU - Monti, R.
AU - Napoli, L.
AU - Ventura, M. T.
AU - De Feo, G.
AU - Fokkens, W. J.
AU - Chavannes, N. H.
AU - Reitsma, S.
AU - Cruz, A. A.
AU - Da Silva, J.
AU - Serpa, F. S.
AU - Larenas-Linnemann, D.
AU - Fuentes-Perez, J. M.
AU - Huerta-Villalobos, Y. R.
AU - Rivero-Yeverino, D.
AU - Rodriguez-Zagal, E.
AU - Valiulis, A.
AU - Dubakiene, R.
AU - Emuzyte, R.
AU - Kvedariene, V.
AU - Annesi-Maesano, I.
AU - Blain, H.
AU - Bonniaud, P.
AU - Bosse, I.
AU - Dauvilliers, Y.
AU - Devillier, P.
AU - Fontaine, J. F.
AU - Pépin, J. L.
AU - Pham-Thi, N.
AU - Portejoie, F.
AU - Picard, R.
AU - Roche, N.
AU - Rolland, C.
AU - Schmidt-Grendelmeier, P.
AU - Kuna, P.
AU - Samolinski, B.
AU - Anto, J. M.
AU - Cardona, V.
AU - Mullol, J.
AU - Pinnock, H.
AU - Ryan, D.
AU - Sheikh, A.
AU - Walker, S.
AU - Williams, S.
AU - Becker, S.
AU - Klimek, L.
AU - Pfaar, O.
AU - Bergmann, K. C.
AU - Mösges, R.
AU - Zuberbier, T.
AU - Roller-Wirnsberger, R. E.
AU - Tomazic, P. V.
AU - Haahtela, T.
AU - Salimäki, J.
AU - Toppila-Salmi, S.
AU - Valovirta, E.
AU - Vasankari, T.
AU - Gemicioǧlu, B.
AU - Yorgancioglu, A.
AU - Papadopoulos, N. G.
AU - Prokopakis, E. P.
AU - Tsiligianni, I. G.
AU - Bosnic-Anticevich, S.
AU - O'Hehir, R.
AU - Ivancevich, J. C.
AU - Neffen, H.
AU - Zernotti, M. E.
AU - Kull, I.
AU - Melén, E.
AU - Wickman, M.
AU - Bachert, C.
AU - Hellings, P. W.
AU - Brusselle, G.
AU - Palkonen, S.
AU - Bindslev-Jensen, C.
AU - Eller, E.
AU - Waserman, S.
AU - Boulet, L. P.
AU - Bouchard, J.
AU - Chu, D. K.
AU - Schünemann, H. J.
AU - Sova, M.
AU - De Vries, G.
AU - Van Eerd, M.
AU - Agache, I.
AU - Ansotegui, I. J.
AU - Bewick, M.
AU - Casale, T.
AU - Dykewick, M.
AU - Ebisawa, M.
AU - Murray, R.
AU - Naclerio, R.
AU - Okamoto, Y.
AU - Wallace, D. V.
AU - Aberer, W.
AU - Akdis, C. A.
AU - Akdis, M.
AU - Aliberti, M. R.
AU - Almeida, R.
AU - Amat, F.
AU - Angles, R.
AU - Arnavielle, S.
AU - Asayag, E.
AU - Asarnoj, A.
AU - Arshad, H.
AU - Avolio, F.
AU - Bacci, E.
AU - Baiardini, I.
AU - Barbara, C.
AU - Barbagallo, M.
AU - Baroni, I.
AU - Barreto, B. A.
AU - Basagana, X.
AU - Bateman, E. D.
AU - Bedolla-Barajas, M.
AU - Beghé, B.
AU - Bel, E. H.
AU - Bennoor, K. S.
AU - Benson, M.
AU - Bertorello, L.
AU - Białoszewski, A. Z.
AU - Bieber, T.
AU - Bialek, S.
AU - Bjermer, L.
AU - Blasi, F.
AU - Blua, A.
AU - Bochenska Marciniak, M.
AU - Bogus-Buczynska, I.
AU - Boner, A. L.
AU - Bonini, M.
AU - Bonini, S.
AU - Bourret, R.
AU - Braido, F.
AU - Briedis, V.
AU - Brightling, C. E.
AU - Brozek, J.
AU - Bucca, C.
AU - Buhl, R.
AU - Buonaiuto, R.
AU - Panaitescu, C.
AU - Burguete Cabañas, M. T.
AU - Burte, E.
AU - Bush, A.
AU - Caballero-Fonseca, F.
AU - Caillaud, D.
AU - Caimmi, D.
AU - Calderon, M. A.
AU - Camargos, P. A.M.
AU - Camuzat, T.
AU - Canfora, G.
AU - Carlsen, K. H.
AU - Carreiro-Martins, P.
AU - Carriazo, A. M.
AU - Carr, W.
AU - Cartier, C.
AU - Castellano, G.
AU - Cepeda, A. M.
AU - Chen, Y.
AU - Chiron, R.
AU - Chivato, T.
AU - Chkhartishvili, E.
AU - Chuchalin, A. G.
AU - Chung, K. F.
AU - Ciaravolo, M. M.
AU - Ciceran, A.
AU - Cingi, C.
AU - Ciprandi, G.
AU - Carvalho Coehlo, A. C.
AU - Colas, L.
AU - Colgan, E.
AU - Coll, J.
AU - Conforti, D.
AU - De Sousa, J. Correia
AU - Cortés-Grimaldo, R. M.
AU - Corti, F.
AU - Costa-Dominguez, M. C.
AU - Courbis, A. L.
AU - Cox, L.
AU - Crescenzo, M.
AU - Custovic, A.
AU - Dahlen, S. E.
AU - D'Amato, G.
AU - Dario, C.
AU - Darsow, U.
AU - De Blay, F.
AU - De Carlo, G.
AU - Dedeu, T.
AU - De Fátima Emerson, M.
AU - De Martino, B.
AU - Motta Rubina, N. P.
AU - Deleanu, D.
AU - Demoly, P.
AU - Denburg, J. A.
AU - Di Capua Ercolano, S.
AU - Di Carluccio, N.
AU - Didier, A.
AU - Dokic, D.
AU - Dominguez-Silva, M. G.
AU - Douagui, H.
AU - Dray, G.
AU - Durham, S. R.
AU - Du Toit, G.
AU - Dykewicz, M. S.
AU - El-Gamal, Y.
AU - Eklund, P.
AU - Farrell, J.
AU - Farsi, A.
AU - Ferreira De Mello, J.
AU - Ferrero, J.
AU - Fink-Wagner, A.
AU - Fiocchi, A.
AU - Forti, S.
AU - Fuentes-Perez, J. M.
AU - Gálvez-Romero, J. L.
AU - Gamkrelidze, A.
AU - Garcia-Aymerich, J.
AU - García-Cobas, C. Y.
AU - Garcia-Cruz, M. H.
AU - Genova, S.
AU - Christoff, G.
AU - Gereda, J. E.
AU - Gerth Van Wijk, R.
AU - Gomez, R. M.
AU - Gómez-Vera, J.
AU - González Diaz, S.
AU - Gotua, M.
AU - Grisle, I.
AU - Guidacci, M.
AU - Guldemond, N. A.
AU - Gutter, Z.
AU - Guzmán, M. A.
AU - Hajjam, J.
AU - Hernández, L.
AU - Hourihane, J. O.B.
AU - Zubrinich, C.
AU - the MASK Study Group
PY - 2019/3/11
Y1 - 2019/3/11
N2 - Aims: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases. Methods: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients. Stakeholders: Include patients, health care professionals (pharmacists and physicians), authorities, patient's associations, private and public sectors. Results: MASK is deployed in 23 countries and 17 languages. 26,000 users have registered. EU grants (2018): MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour). Lessons learnt: (i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases.
AB - Aims: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases. Methods: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients. Stakeholders: Include patients, health care professionals (pharmacists and physicians), authorities, patient's associations, private and public sectors. Results: MASK is deployed in 23 countries and 17 languages. 26,000 users have registered. EU grants (2018): MASK is participating in EU projects (POLLAR: impact of air POLLution in Asthma and Rhinitis, EIT Health, DigitalHealthEurope, Euriphi and Vigour). Lessons learnt: (i) Adherence to treatment is the major problem of allergic disease, (ii) Self-management strategies should be considerably expanded (behavioural), (iii) Change management is essential in allergic diseases, (iv) Education strategies should be reconsidered using a patient-centred approach and (v) Lessons learnt for allergic diseases can be expanded to chronic diseases.
KW - App
KW - Asthma
KW - Care pathways
KW - DG Santé
KW - MASK
KW - mHealth
KW - Rhinitis
UR - http://www.scopus.com/inward/record.url?scp=85062865821&partnerID=8YFLogxK
U2 - 10.1186/s13601-019-0252-0
DO - 10.1186/s13601-019-0252-0
M3 - Review Article
C2 - 30911372
AN - SCOPUS:85062865821
SN - 2045-7022
VL - 9
JO - Clinical and Translational Allergy
JF - Clinical and Translational Allergy
IS - 1
M1 - 16
ER -